What’s Next for Enanta Pharmaceuticals Inc (ENTA) After Today’s Huge Increase?

July 11, 2017 - By Louis Casey

Investors sentiment decreased to 1.47 in 2016 Q4. Its down 0.06, from 1.53 in 2016Q3. It fall, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
568,686 were reported by Acadian Asset Mngmt Lc. Alliancebernstein Ltd Partnership owns 132,060 shares or 0% of their US portfolio. Blackrock Institutional Na has 459,134 shares for 0% of their portfolio. Gsa Cap Ptnrs Limited Liability Partnership owns 0.15% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 77,309 shares. Eqis Capital Mngmt reported 35,326 shares. State Bank Of Montreal Can reported 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Blackrock Japan Ltd holds 0% or 430 shares. New York State Teachers Retirement System has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Aqr Capital Limited Liability, a Connecticut-based fund reported 113,794 shares. Blackrock Inc stated it has 8,564 shares. Prelude Mngmt Ltd Com invested in 0.02% or 6,002 shares. Ls Invest Advsrs Lc accumulated 0% or 483 shares. International Group has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Weiss Multi reported 20,000 shares stake. Qs Investors Limited Liability has invested 0.02% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! About 439,199 shares traded or 120.01% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since July 11, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $649.47 million company. It was reported on Jul, 11 by Barchart.com. We have $38.92 PT which if reached, will make NASDAQ:ENTA worth $45.46M more.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals Inc had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Zacks on Friday, August 7. TheStreet downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Saturday, August 8 to “Buy” rating. The rating was upgraded by JMP Securities to “Mkt Outperform” on Friday, October 23. The firm has “Market Perform” rating by JMP Securities given on Thursday, April 28. The company was downgraded on Friday, October 23 by Barclays Capital. On Tuesday, July 11 the stock rating was upgraded by JMP Securities to “Market Outperform”. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Businesswire.com which released: “Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on …” on January 06, 2017, also Streetinsider.com with their article: “Enanta Pharma (ENTA) Presents New Data on EDP-938” published on June 26, 2017, Benzinga.com published: “12 Biggest Mid-Day Gainers For Tuesday” on July 11, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta: Robust Balance Sheet With Numerous Catalysts” published on October 31, 2016 as well as Businesswire.com‘s news article titled: “Enanta Pharmaceuticals to Present at the HC Wainwright 1” with publication date: March 27, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $649.47 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: